A dissection of five years' biopharma buyout spending reveals that most deals are struck over preclinical and mid-stage assets, while buyers remain most interested…
The takeover of Celgene has disrupted pharma’s conventional wisdom on which companies should merge and when. This is how things now stand.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.
A return to tuck-in deals – sort of.
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.